Trihydroxycinnamoyl spermidines (THCSpd) are plant specialized
metabolites with promising pharmacological activities as antifungals,
antibacterial, antiviral, and antidepressant drugs. However, their
characterization and potential pharmaceutical exploitation are greatly
impaired by the sourcing of these compounds, restricted to the pollen
of core Eudicot plant species. In this work, we developed a precursor-directed
biosynthesis of THCSpd in yeast using a dual enzymatic system based
on 4-coumarate-CoA ligases (4CL) and spermidine N-hydroxycinnamoyltransferases (SHT). The system relies on the yeast
endogenous spermidine pool and only requires hydroxycinnamic acids
as exogenous precursors. By exploring 4CL isoforms and SHT diversity
among plants, we have driven the production of 8 natural THCSpd, using
single or mixed hydroxycinnamic acid precursors. Substrate promiscuities
of 4CL and SHT were genuinely exploited to produce 8 new-to-nature
THCSpd from exotic hydroxycinnamic and dihydrohydroxycinnamic acids,
together with 3 new-to-nature THCSpd containing halogenated hydroxycinnamoyl
moieties. In this work, we established a versatile and modular biotechnological
production platform allowing the tailor-made THCSpd synthesis, constituting
pioneer metabolic engineering for access to these valuable natural
products.